Candel Orphan Drug Designation for CAN-2409 for Treatment of Pancreatic Cancer

 Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer.

https://www.globenewswire.com/news-release/2024/04/11/2861549/0/en/Candel-Therapeutics-Receives-FDA-Orphan-Drug-Designation-for-CAN-2409-for-the-Treatment-of-Pancreatic-Cancer.html